Diabetes Care

Gliclazide MR, XR and Standard Tablets and Why Release Form Matters

Read the full gliclazide label and prepare for everyday questions about meals, low glucose and changes between tablet presentations.

By Global Medicines ExportUpdated: Educational article

Formulation reference

Reading a gliclazide presentation

The UK label examples identify distinct products. They are not a conversion schedule for a different brand or country.

Ingredient, release and schedule checks

PresentationWhat the wording identifiesPractical check
UK gliclazide 80 mg standard tabletAn immediate-release reference formulationUse the prescribed meal and tablet schedule
UK Gliclazide Krka 30 mg modified-release tabletA named modified-release formulationIts label describes one daily intake at breakfast
Gliclazide XR catalogue presentationManufacturer release wording and strength per tabletConfirm the exact brand leaflet before changing products
Gliclazide plus another ingredientA fixed combination medicineRecord each ingredient and strength

What is the difference between standard and MR or XR gliclazide?

Gliclazide helps lower blood glucose by increasing insulin release. It is used for type 2 diabetes. Standard tablets and modified-release products are designed differently, which can change the amount and timing prescribed. A comparison needs the full product name, including MR, XR or prolonged-release wording.

This guide uses UK gliclazide 80 mg and Gliclazide Krka 30 mg modified-release information as examples. A clinician can plan a change using the specific labels and glucose monitoring. Do not calculate a replacement by matching the milligram number alone.

What should you copy from the carton?

Record the ingredient, strength per tablet, release description, manufacturer and prescribed tablet count. If a combination includes metformin or another medicine, give each ingredient its own strength. Photograph both the front label and the directions when asking a pharmacist about a change.

The Gliclazide 30 mg XR Tablets and Gliclazide 120 mg XR Tablets listings identify separate GME catalogue presentations. A listed strength identifies one presentation and does not establish that it is suitable for a particular prescription. Ask for the exact offered pack and leaflet.

How do meals and tablet timing fit together?

Follow the timing printed for your exact product. The UK Krka 30 mg modified-release reference describes taking the prescribed daily amount at breakfast and swallowing the tablets whole. Standard tablets can use a different schedule. If your usual breakfast is very small or you work changing shifts, discuss how the prescription should fit your actual meals.

Before fasting or substantially changing carbohydrate intake, ask for a medicine and glucose-check plan. A record of meal times, tablets and readings can show whether a low followed a delayed meal. The guide to walking after meals explains why extra activity also belongs in that record.

How do you recognise and respond to a low?

Shaking, sweating, hunger, dizziness, blurred vision or confusion can be signs of hypoglycaemia. Check glucose if you can and follow your agreed treatment plan promptly. NHS guidance uses a glucose below 4 mmol/L as the usual threshold for a low and advises fast-acting sugar followed by repeat checks.

Teach someone close to you what to do. If a person is unconscious, having a seizure or cannot swallow safely, give no food or drink by mouth and call emergency services. Use prescribed glucagon if available and someone knows how. Repeated lows or an episode that returns after initial treatment need medical advice because sulfonylurea-related lows can persist.

What makes low glucose more likely?

Discuss missed meals, prolonged or strenuous exercise, alcohol, kidney or liver problems and other glucose-lowering medicines. Gliclazide can contribute to low glucose even when a meal plan has worked well before. A change in appetite or activity can make the previous plan harder to follow.

For a review, describe the time of the low, the last meal, the last tablet, treatment used and whether the symptoms returned. Bring your meter record rather than relying on an average alone. HbA1c and fasting blood sugar explains how a longer-term result can coexist with individual high or low readings.

Which other medicines should a pharmacist check?

Mention new prescriptions, antibiotics, pain relievers and treatments bought for thrush. The UK gliclazide reference contraindicates systemic miconazole and miconazole mouth gel because of severe low-glucose risk. Fluconazole and some other medicines also require a careful check. Give the pharmacist the route as well as the ingredient name.

If a clinician starts or stops a corticosteroid, tell the diabetes team because your glucose pattern may change. Bring a single current list including other diabetes medicines. Ask whether extra monitoring is needed during the change and how to contact the team if readings move outside your agreed range.

What if you forget a tablet or take an extra one?

Read the missed-dose instructions supplied with your product. The UK modified-release reference says a forgotten dose must not be made up by increasing the following day's amount. If the timing is unclear, ask a pharmacist with the product and usual schedule to hand.

An extra dose can cause a dangerous low. Get urgent medical advice if you have taken more than prescribed, even if you initially feel well. Say how many tablets, their release form and when they were taken. Do not drive yourself if you are unwell or your glucose may be low.

How do you judge whether the current plan is working?

Your team may use HbA1c, selected glucose readings and your history of symptoms to assess treatment. Feeling well does not establish that glucose is in range. Equally, frequent lows require attention even if the HbA1c appears satisfactory.

Agree on the target, the date of the next review and which results require earlier contact. If meals are unpredictable, if you regularly miss tablets or if lows make exercise difficult, explain that practical problem. The clinician can review whether the current formulation and overall treatment remain a good fit.

Export product support

Need product, pack, and documentation details?

Global Medicines Export can support international B2B enquiries for product availability, strengths, pack information, quotation coordination, and shipment documentation review.

Common questions

Are MR and XR the same instructions on every brand?

They are release descriptions used by manufacturers. Check the full leaflet for the exact product rather than inferring its schedule from the letters alone.

Can I replace an 80 mg standard tablet with an 80 mg modified-release product?

Have a prescriber or pharmacist check the proposed change. Ingredient strength, release design, tablet count and glucose response all matter.

Can I crush a modified-release tablet to make it easier to swallow?

Check with a pharmacist before altering it. The referenced Krka product is swallowed whole. Other presentations need their own handling instructions.

Can a low happen after exercise?

Yes. Discuss a plan if you take gliclazide and increase activity. Record the timing of meals, tablets, activity and readings if lows occur.

Should I mention miconazole mouth gel?

Yes. The UK gliclazide reference identifies miconazole mouth gel as a contraindicated combination. Tell the pharmacist before using a thrush treatment.

Why can low glucose return after I have treated it?

Sulfonylureas can have a continuing effect. Seek medical advice for a severe, prolonged or recurring low and follow your agreed repeat-check plan.

What should I ask before fasting?

Ask how the medicine, meals and monitoring should be arranged and what symptoms or readings mean you should break the fast and seek help.

Important medical note

This article is for general educational information only. It is not medical advice, diagnosis, or a treatment plan. Medicines should be used only under the guidance of a qualified healthcare professional. Product availability, export documentation, and quotation support do not imply that a medicine is appropriate for any individual patient.

References